---
schema_version: "secwatch.filing_event.v1"
accession: "0001613103-24-000140"
form_type: "8-K"
ticker: "MDT"
cik: "0001613103"
company_name: "Medtronic plc"
filed_at: "2024-08-20T23:59:59+00:00"
generated_at: "2026-05-31T08:28:26.012976+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Medtronic Q1 FY25: revenue $7.9B (+2.8%), GAAP EPS $0.80, non-GAAP EPS $1.23; raises FY25 guidance

## Summary
- Revenue $7.915B (adjusted $8.004B), up 5.3% organic; GAAP EPS $0.80, non-GAAP EPS $1.23 (+8% constant currency).
- Raises FY25 organic revenue growth guidance to 4.5%-5% (from 4-5%) and non-GAAP EPS guidance to $5.42-$5.50.
- Cardiovascular $3.007B (+6.9% organic) driven by CRM and PFA; Neuroscience $2.317B (+5.3% organic) with Neuromodulation up low-double digits.
- Diabetes $647M (+12.6% organic) on MiniMed 780G; Simplera CGM FDA approved, Abbott partnership for future integrated CGM.
- Medical Surgical $1.996B (+1.0% organic) with SE low-single digit growth and ACM flat.

## SEC filing metadata
- accession: 0001613103-24-000140
- form_type: 8-K
- ticker: MDT
- cik: 0001613103
- company_name: Medtronic plc
- filed_at: 2024-08-20T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1613103/000161310324000140/0001613103-24-000140-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1613103/000161310324000140/mdt-20240820.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001613103-24-000140
- JSON: https://secwatch.observer/filing/0001613103-24-000140.json
- Plain text: https://secwatch.observer/filing/0001613103-24-000140.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.